Valuation: Positron Corporation

Market Cap 55.02M 49.13M 45.39M 41.13M 76.95M 5.22B 78.22M 546M 216M 2.74B 206M 202M 8.63B P/E 2024
-11x
P/E 2025 -4.87x
Enterprise Value 53.88M 48.11M 44.45M 40.28M 75.36M 5.11B 76.61M 535M 212M 2.68B 202M 198M 8.45B EV / Sales 2024
49.4x
EV / Sales 2025 116x
Free-Float
45.36%
Yield 2024 *
-
Yield 2025 -
1 day+2.15%
1 week+22.58%
Current month+6.26%
1 month+1.06%
3 months+18.75%
6 months+0.53%
Current year+13.77%
1 week 1.63
Extreme 1.63
1.91
1 month 1.43
Extreme 1.43
2
Current year 1.43
Extreme 1.43
2.74
1 year 1.27
Extreme 1.27
2.74
3 years 0.87
Extreme 0.87
2.94
5 years 0.07
Extreme 0.0682
2.94
10 years 0
Extreme 0
2.94
Manager TitleAgeSince
President 53 2018-02-26
Sales & Marketing - 2022-06-23
Corporate Officer/Principal 40 2018-05-24
Director TitleAgeSince
Chairman 53 -
Director/Board Member - -
Change 5-day change 1-year change 3-year change Capi.($)
+2.15%+22.58%+30.14%+36.20% 55.02M
-0.40%-2.34%+17.82%+45.91% 249B
+0.33%+0.64%+3.49%+12.96% 162B
+1.90%+6.00%-17.96%+65.92% 157B
-0.70%+2.93%-55.38%-8.86% 66.22B
+0.15%+4.09%+10.82%+65.55% 52.3B
+0.24%+0.99%-15.19%-10.88% 52.18B
-1.13%+2.85%+16.39%+28.99% 51.34B
-0.47%+0.06%+17.37%+58.29% 48.79B
-0.42%+3.83%+27.55%+77.45% 44.57B
Average +0.17%+2.04%+3.50%+37.15% 88.35B
Weighted average by Cap. +0.14%+1.50%+1.37%+38.41%

Financials

2024 2025
Net sales 588K 525K 485K 439K 822K 55.77M 835K 5.83M 2.31M 29.22M 2.2M 2.16M 92.12M 461K 412K 381K 345K 645K 43.81M 656K 4.58M 1.81M 22.95M 1.73M 1.69M 72.36M
Net income -2.38M -2.12M -1.96M -1.78M -3.33M -226M -3.38M -23.62M -9.35M -118M -8.93M -8.74M -373M -10.6M -9.47M -8.75M -7.93M -14.83M -1.01B -15.08M -105M -41.67M -527M -39.79M -38.95M -1.66B
Net Debt 1.42M 1.27M 1.18M 1.06M 1.99M 135M 2.03M 14.14M 5.6M 70.85M 5.35M 5.23M 223M -1.14M -1.01M -937K -849K -1.59M -108M -1.62M -11.28M -4.47M -56.51M -4.26M -4.17M -178M
Projected Income Statement - Annual - Positron Corporation
Logo Positron Corporation
Positron Corporation is a medical technology company focused to advancing the Positron Emission Tomography (PET) imaging modality through the development, manufacturing, and commercialization of its PET and PET-CT (Positron Emission Tomography/Computed Tomography) imaging systems along with providing comprehensive clinical services to nuclear medicine healthcare providers across North America. The Company specializes in the field of cardiac PET imaging, the gold standard in cardiac diagnostics. The Company’s imaging portfolio includes dedicated PET and 3D PET-CT 64-Slice systems, both designed to expand access to advanced molecular imaging. Additionally, it is preparing to introduce its 4D PET-CT 64-Slice scanner in nuclear cardiology. Its products, Attrius PET and NeuSight PET-CT 64- Slice scanner, provide a molecular imaging solution, enabling healthcare providers with diagnostic accuracy for cardiac and oncologic applications.
Employees
10
Date Price Change Volume
26-10-23 US$1.675 +2.76% 110
26-10-22 US$1.630 -0.85% 5,469
26-10-21 US$1.644 -4.57% 819
26-10-20 US$1.723 +1.34% 13,869
26-10-19 US$1.700 +9.68% 13,445
  1. Stock Market
  2. Stocks
  3. POSC Stock